Renowned digital health company ResApp Health Limited (ASX:RAP) announced on Friday that it has secured a one-year, non-exclusive licensing agreement with AstraZeneca K.K. to licence its cough counting technology for use in a programme to support asthma patients.
ResApp is a Company involved in developing smartphone applications for the diagnosis and management of respiratory diseases.
As per the deal, ResApp’s cough counting technology will be integrated into AstraZeneca’s direct-to-customer asthma management smartphone application to help patients monitor symptoms in the home setting and support them in managing their asthma.
AstraZeneca’s asthma monitoring application is presently under development and is expected to launch in the coming months.
Meanwhile, the stock was found trading at A$0.067 per share, up 15.517%, with market capitalisation at A$43.97 million at 11:51 AM AEDT.